 WALTHAM, Mass., Nov. 4, 2021 PRNewswire -- Syndax Pharmaceuticals, Inc. Nasdaq: SNDX, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that updated data from both of its ongoing SNDX-5613 and axatilimab programs will be featured during oral sessions at the 63rd American Society of Hematology ASH Annual Meeting and Exposition being held December 11-14, 2021. 